DSO Rollover Equity: What Dentists Need to Know Before Signing

When a DSO offers to acquire your practice for $3.5M, the headline number is rarely all cash. A significant portion — typically 15–30% — comes back to you as rollover equity: an ownership stake in the DSO's parent company that you can't sell until the DSO itself achieves a liquidity event. That equity may be worth exactly what the term sheet says, or it could be worth considerably less. The difference depends on terms most dentists don't read carefully enough before signing.

This guide explains how rollover equity works, how the tax treatment differs from your cash proceeds, what risks are often buried in the fine print, and what to negotiate before you agree to take equity instead of cash.

How rollover equity fits into a DSO deal

A typical large-DSO offer to a practice producing $1.5M in collections at a 30% EBITDA margin might be structured as follows:

The rollover equity is presented as a way to "participate in the upside" as the DSO grows and eventually sells or recapitalizes. In theory, if the DSO platform grows from a 6× EBITDA multiple today to a 9× multiple at exit, your $840,000 in equity could be worth $1.26M. In practice, the outcome depends on the DSO's financial structure in ways that are difficult to assess from the outside.

How rollover equity is structured

DSO rollover equity is almost always structured as an interest in the DSO's holding company — a private entity, usually a Delaware LLC or C-corporation backed by a private equity sponsor. The specific structure matters for how it's valued, taxed, and when you can exit.

LLC units vs. corporate stock

If the holding company is an LLC, you receive membership units. If it's a C-corporation, you receive shares of common or preferred stock. The tax treatment at exit differs: LLC unit gains flow through as capital gains directly to you; corporate stock gains are also capital gains but the entity structure may introduce other complexities (phantom income allocations from LLCs being one example).

Series and preferences

PE-sponsored DSOs typically have a complex capitalization structure. The private equity firm holds preferred stock or senior equity units with a liquidation preference — meaning they get paid first, and at a guaranteed return (often 1.5–2× their invested capital), before common equity holders see anything. You are almost certainly being offered common equity or common equivalent units. In a scenario where the DSO sells for 20% less than its current valuation, the preferred investors may be fully protected while your common equity is worth nothing.

Waterfall math matters

Ask the DSO for a cap table showing the full ownership structure and a distribution waterfall model showing what you receive at various exit valuations. If they won't provide this before you sign, that's a red flag. You need to understand exactly how exit proceeds are distributed before you can assess whether your equity is fairly priced.

The valuation problem

The $840,000 figure on your term sheet is the DSO's stated valuation of your equity — a number they calculated. It represents an entry price, not a market price, because there is no market: the equity is private and illiquid. You have essentially three ways to assess whether that entry price is fair:

1. Look at the DSO's EBITDA multiple. If the DSO is valued at 8× platform EBITDA and your practice contributes $450,000 in EBITDA, your practice implies $3.6M of value. The equity rollover on a $3.6M practice at 24% is $864,000 — roughly in line. But if the DSO is applying a lower EBITDA multiple to your rollover valuation than they used to calculate the total deal consideration, you are selling equity at a premium and buying it back at a discount.
2. Assess the DSO's financial health. Request audited financials or at minimum a summary income statement and balance sheet for the platform. Highly leveraged DSOs — those carrying $200M+ in debt relative to $30M in EBITDA — have limited margin for error. Several DSO platforms with this profile have filed for bankruptcy or undergone debt restructuring since 2022.¹
3. Hire a transaction advisor. A fee-only financial planner or dental M&A attorney can review the term sheet and cap table independently. This typically costs $3,000–$8,000 and is almost always worth it on a $3M+ transaction.

Tax treatment: at closing and at the liquidity event

The tax treatment of rollover equity is one of its most misunderstood features. Here is what actually happens:

At closing

The cash portion of your sale proceeds (goodwill, tangible assets) is taxable in the year of closing — typically at long-term capital gains rates (20% federal) plus the 3.8% Net Investment Income Tax (NIIT) for high earners, plus state income tax. See our dental practice sale guide for a full breakdown of how the sale is taxed.

The rollover equity portion is generally not taxable at closing. Under IRC §721 (for LLC interests) or §351 (for corporate stock contributions), contributing your existing equity interest in exchange for an interest in the acquiring entity can be structured as a tax-deferred exchange. The DSO's transaction attorneys typically structure the rollover to achieve this deferral — ask them to confirm this explicitly and get it in writing.

At the liquidity event

When the DSO sells, recapitalizes, or IPOs, your rollover equity is liquidated and you receive your share of the proceeds. That gain is taxed as long-term capital gains (20% + 3.8% NIIT = 23.8% maximum federal rate) if you have held the equity for more than 12 months — which is almost always true given that liquidity events typically occur 5–10 years after your initial sale.²

Important: earnout payments received under a continued-employment arrangement are generally taxed as ordinary income, not capital gains, because the IRS treats them as compensation for services. This is distinct from the rollover equity — make sure your attorney structures any performance-based payment as a contingent purchase price, not compensation, if you want capital gains treatment.

Phantom income from LLC interests

If you hold LLC membership units, you may receive annual K-1 allocations of taxable income even in years when you receive no cash distributions. This occurs when the LLC has taxable income (interest, gains) that it allocates to unit holders without distributing cash. Plan for the possibility of a K-1 showing $50,000+ in taxable income in a year when you received zero dollars from the DSO.

QSBS consideration

Qualified Small Business Stock (QSBS) under IRC §1202 allows up to 100% of capital gains to be excluded from federal tax on qualifying stock (up to $15M under the OBBBA, effective 2025).³ DSO rollover equity generally does not qualify for QSBS for two reasons: (1) IRC §1202(e)(3) specifically excludes businesses in the field of health from QSBS status; (2) most DSO platforms have aggregate gross assets far exceeding the $50M threshold required at the time of stock issuance. Consult your CPA or tax attorney to confirm whether QSBS applies to the specific DSO entity structure before signing — occasionally holding company structures are engineered to qualify, but this is uncommon.

Liquidity pathways and realistic timelines

DSO rollover equity has no public market. You cannot sell it when you want. Liquidity requires a triggering event, and the timeline is outside your control:

In a recapitalization scenario — the most common DSO liquidity event — you may be required to roll some equity again into the new holding structure. A dentist who sold in 2019 and expected a 2024 exit may instead be re-rolling into a third PE fund and looking at a 2029 liquidity event. Build a financial plan that does not depend on DSO equity proceeds arriving by any specific date.

What to negotiate before you sign

Rollover equity terms are negotiable, especially for larger practices. Before you accept the equity component at face value, push for:

1. Anti-dilution protection

Without anti-dilution protection, the DSO can issue new equity to future acquisitions or management at lower valuations, diluting your percentage interest without your consent. Request weighted-average anti-dilution as a minimum. Full ratchet anti-dilution is stronger but uncommon in DSO transactions.

2. Information rights

You should receive annual audited financial statements and quarterly unaudited financials while you hold equity. Information rights are standard in private equity agreements but sometimes omitted in DSO roll-up documentation. Without them, you have no way to monitor the health of the platform holding your $840,000.

3. Tag-along rights

Tag-along rights allow you to sell your equity on the same terms as the DSO's control investors if they sell their stake. Without tag-along rights, the PE firm can exit at a premium while you remain locked in to the new buyer's terms.

4. Put option or redemption right

A put option gives you the right to sell your equity back to the DSO at a formula price after a specified holding period (typically 5 years). This provides a floor on your downside and a guaranteed exit if the DSO fails to achieve a liquidity event. Not all DSOs will grant this, but it's worth asking.

5. Drag-along protection

Drag-along provisions require minority holders (you) to vote in favor of a transaction that the majority approves. This is standard and usually unavoidable. Negotiate minimum price thresholds in the drag-along — a clause that you cannot be dragged into a sale at less than 1× your original equity valuation, for example.

6. Valuation methodology for any formula-based exit

If the agreement includes a redemption price calculated by formula (e.g., 4× EBITDA), agree on the EBITDA definition in writing. EBITDA can be calculated to show almost any number depending on what add-backs the DSO includes. A clear, audited definition protects you from receiving far less than you expect at a redemption event.

Red flags to watch for

• No cap table provided before signing. You cannot evaluate your equity without knowing the complete ownership structure. Any DSO that refuses to share this pre-signing is hiding something.
• Equity in a different entity than you expect. Confirm that your equity is in the platform's operating holding company, not a sub-entity (subsidiary, regional holding co.) with limited upside and the same downside risk.
• Excessive earnout tied to your continued employment. Earnouts conditioned on your continued production are compensation, not purchase price. They're taxed as ordinary income and create a disguised employment obligation.
• Rollover requirement on a recapitalization. Understand whether you can cash out fully in the first liquidity event or whether you're contractually required to roll equity into the next fund.
• High leverage on the platform. Debt-to-EBITDA above 6× means the platform has very little cushion. A single bad year in patient volume or a rate spike on variable debt can quickly impair common equity holders.
• No information rights or audit rights in the agreement. This is a governance red flag regardless of deal size.

Building your personal financial plan around DSO equity

The core planning principle: treat your DSO rollover equity as a speculative, illiquid asset with an uncertain timeline. Your retirement plan, portfolio, and cash flow projections should be stress-tested against scenarios where the equity is worth zero — because in a distressed platform, it can be.

• Max out tax-advantaged contributions in the transition period. Your final years under the walk-out employment agreement are often high-income years. The DSO's 401(k) plan allows up to $72,000 in annual contributions at maximum income (2026 limits: $24,500 deferral + employer match/profit-sharing). Use these contributions to reduce your ordinary income and build a diversified retirement account independent of your DSO equity.
• Diversify your liquid assets aggressively. The cash proceeds from your sale — after taxes — should be invested in a diversified portfolio. You've already taken substantial concentration risk in your DSO equity position; your liquid assets should not replicate that risk.
• Update your estate plan to reflect the new asset. DSO equity, particularly LLC units, can create complexity in estate planning. Update your buy-sell agreement (now dissolved), revise beneficiary designations, and consider whether trust structures are appropriate given the new asset mix.
• Model the Roth conversion window. If the DSO employment agreement phases out within 2–3 years and your ordinary income drops significantly, the gap between your sale year income and your pre-Medicare income may be an optimal Roth conversion window. See our Roth conversion guide for the bracket-filling framework.